Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2017

View Archived Issues

Bayer initiates phase I study of BAY-1895344 in advanced solid tumors and lymphomas

Dana-Farber Cancer Institute begins phase I study of rQNestin34.5v.2 for recurrent malignant glioma

TRPA1 involved in inflammation in arthritis can be inhibited by dexamethasone and aurothiomalate

Lilly and Nektar Therapeutics to co-develop NKTR-358

UCB announces promising phase IIb data for bimekizumab in patients with chronic plaque psoriasis

GSK-2878175 leads to reduction in HCV RNA in healthy and treatment-naive patients with CHC

EMA gives PRIME designation to Tocagen's Toca-511

Orchard Therapeutics' OTL-101 wins FDA rare pediatric disease designation

Seattle Genetics enters clinical collaboration with Genentech

University of Chile patents compounds for treating MDR bacterial infections

Hitgen presents histone deacetylase inhibitors

Hitgen divulges ROCK1 and ROCK2 inhibitors

Shanghai Fochon Pharmaceutical and Fochon Pharma divulge SLC22A12 inhibitors

CDK4 and CDK6 inhibitors reported in Shanghai Fochon Pharmaceutical patent

EMA committee recommends against approval of Onzeald

EMA committee recommends approval of Vimpat for focal-onset seizures in children

FDA expands Yervoy indication to include pediatric patients

FDA accepts sBLAs for Opdivo 4-week dosing schedule

GeoVax enters collaboration to advance LASV vaccine candidate

Pfizer reports results from phase III study of bevacizumab biosimilar

Evotec reaches milestone in endometriosis alliance with Bayer

Cytori Therapeutics reports topline data from STAR trial in scleroderma

Renflexis launched in U.S.

Shionogi reports phase III results on S-033188

EMA's CHMP recommends Verkazia for severe vernal keratoconjunctivitis in children and adolescents

Intrarosa launched in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...